Prostate Cancer Diagnostics and Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Prostate Cancer Diagnostics and Therapy Market is Segmented by Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Other Types), Modality (Diagnosis and Treatment), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Report Offers the Value (in USD Million) for the Above-Mentioned Segments.

Prostate Cancer Diagnostics and Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Prostate Cancer Diagnostics & Therapy Market Size

Prostate Cancer Diagnostics and Therapy Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 14.41 Billion
Market Size (2030) USD 21.96 Billion
CAGR (2025 - 2030) 8.80 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Prostate Cancer Diagnostics and Therapy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Prostate Cancer Diagnostics And Therapy Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Prostate Cancer Diagnostics & Therapy Market Analysis

The Prostate Cancer Diagnostics And Therapy Market size is estimated at USD 14.41 billion in 2025, and is expected to reach USD 21.96 billion by 2030, at a CAGR of 8.8% during the forecast period (2025-2030).

Cancer diagnosis and treatment care were impacted by the sudden emergence of COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients, especially prostate cancer patients, are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by malignancy and anticancer treatment. Thus, they are majorly suggested to stay at home and avoid all non-emergent diagnoses and treatment. According to the Union for International Cancer Control (UICC) in May 2020, there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. Such decreases in cancer diagnostics are expected to have a short-term decline in demand during the pandemic period. However, the relaxation of the strict regulations is expected to contribute to the reopening of diagnostic clinics and research activities for prostate cancer, thereby contributing to the growth of the market during the post-pandemic period.

The major factor attributing to the growth of the market studied is an aging population and a high prevalence rate of prostate cancer. According to Globocan 2020, prostate cancer is the second most common type of cancer in the male population. As per the data published by the same source, the prevalence of prostate cancer was found to be 1,414,259, or 7.3% of the total cancer cases worldwide. As prostate cancer is more common in the elderly population, the rising aging population in the world is also expected to propel market growth. For instance, according to the World Population Prospects 2022 published by the United Nations, the share of global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Such an increase in the geriatric population who are prone to developing prostate cancer is expected to drive the growth of the market over the forecast period.

Furthermore, the rising product approvals and developments are expected to contribute to the growth of the studied market. For instance,in March 2022, the United States Food and Drug Administration approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. Therefore, these will lead to increased adoption of prostate cancer therapies, driving market growth.

Hence, owing to all the aforementioned factors, the market is anticipated to propel at high growth rates. However, the high cost of prostate cancer drugs and the low success rate of clinical trials are expected to hinder market growth.

Prostate Cancer Diagnostics & Therapy Industry Overview

The market for prostate cancer diagnostics and therapy is highly competitive due to the presence of a number of market players. Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as major players lies primarily within specific product markets. Some of the key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG. 

Prostate Cancer Diagnostics & Therapy Market Leaders

  1. Bayer AG

  2. AstraZeneca PLC

  3. Sanofi-Aventis

  4. Thermo Fisher Scientific

  5. F. Hoffmann-La Roche Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
Prostate Cancer Diagnostics and Therapy Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Prostate Cancer Diagnostics & Therapy Market News

  • In April 2022, the Milton and Carroll Petrie Department of Urology at Mount Sinai launched the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit to support prostate health in the Black community.
  • In March 2022, the United States Food and Drug Administration approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Prostate Cancer Diagnostics & Therapy Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
    • 5.2.1.1 Tissue Biopsy
    • 5.2.1.2 Transrectal Ultrasound
    • 5.2.1.3 Clinical Laboratory Examination
    • 5.2.1.3.1 Prostate-specific Antigen Testing
    • 5.2.1.3.2 Urine Testing
    • 5.2.1.4 Diagnostic Imaging
    • 5.2.2 Treatment
    • 5.2.2.1 Surgery
    • 5.2.2.2 Radiation Therapy
    • 5.2.2.3 Therapeutics
    • 5.2.2.3.1 Hormone Therapy
    • 5.2.2.3.2 Chemotherapy
    • 5.2.2.3.3 Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Ipsen SA
    • 6.1.7 Johnson & Johnson Services Inc.
    • 6.1.8 Koninklijke Philips NV
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Pfizer Inc.
    • 6.1.11 Sanofi-Aventis
    • 6.1.12 Thermo Fisher Scientific
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Prostate Cancer Diagnostics & Therapy Industry Segmentation

As per the scope of the report, prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer. The Prostate Cancer Diagnostics and Therapy Market is segmented by Type (Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma, Small Cell Carcinoma, and Other Types), Modality (Diagnosis and Treatment), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.

By Type Benign Prostatic Hyperplasia
Prostatic Adenocarcinoma
Small Cell Carcinoma
Other Types
By Modality Diagnosis Tissue Biopsy
Transrectal Ultrasound
Clinical Laboratory Examination Prostate-specific Antigen Testing
Urine Testing
Diagnostic Imaging
Treatment Surgery
Radiation Therapy
Therapeutics Hormone Therapy
Chemotherapy
Other Treatments
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Prostate Cancer Diagnostics & Therapy Market Research FAQs

How big is the Prostate Cancer Diagnostics And Therapy Market?

The Prostate Cancer Diagnostics And Therapy Market size is expected to reach USD 14.41 billion in 2025 and grow at a CAGR of 8.80% to reach USD 21.96 billion by 2030.

What is the current Prostate Cancer Diagnostics And Therapy Market size?

In 2025, the Prostate Cancer Diagnostics And Therapy Market size is expected to reach USD 14.41 billion.

Who are the key players in Prostate Cancer Diagnostics And Therapy Market?

Bayer AG, AstraZeneca PLC, Sanofi-Aventis, Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd. are the major companies operating in the Prostate Cancer Diagnostics And Therapy Market.

Which is the fastest growing region in Prostate Cancer Diagnostics And Therapy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Prostate Cancer Diagnostics And Therapy Market?

In 2025, the North America accounts for the largest market share in Prostate Cancer Diagnostics And Therapy Market.

What years does this Prostate Cancer Diagnostics And Therapy Market cover, and what was the market size in 2024?

In 2024, the Prostate Cancer Diagnostics And Therapy Market size was estimated at USD 13.14 billion. The report covers the Prostate Cancer Diagnostics And Therapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Prostate Cancer Diagnostics And Therapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Prostate Cancer Diagnostics and Therapy Industry Report

Statistics for the 2025 Prostate Cancer Diagnostics And Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Prostate Cancer Diagnostics And Therapy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Prostate Cancer Diagnostics And Therapy Market Report Snapshots